Phaseline

Companies › CARsgen Therapeutics

CARsgen Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CT011 CAR-GPC3 T Cells Injection
Anti-GPC3 CAR-T cell therapy
GPCSPhase 1HCCDec 2026
CT041 autologous CAR T-cell injection
anti-CLDN18.2 chimeric antigen receptor T-cell
CLDN18Phase 1Pancreatic Cancer; Gastric Cancer; Gastric AdenocarcinomaDec 2026
zevor-cel (CT053)
autologous CAR-T cell therapy targeting BCMA
–Phase 1Multiple MyelomaDec 2034

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05911217CT041 autologous CAR T-cell injectionPhase 1Pancreatic CancerOncologyDec 2026
NCT06560827CT011 CAR-GPC3 T Cells InjectionPhase 1HCCOncologyDec 2026
NCT03915184zevor-cel (CT053)Phase 1Multiple MyelomaOncologyDec 2034
NCT04404595CT041 autologous CAR T-cell injectionPhase 1Gastric CancerOncologySep 2035
NCT04581473CT041 autologous CAR T-cell injectionPhase 1Gastric AdenocarcinomaOncologyJun 2038

Targets

CLDN18 (1) GPCS (1)

Companies with the same targets

Astellas AstraZeneca RemeGen Shanghai Institute Of Biological Products Beijing Biotech Sichuan Kelun-Biotech Biopharmaceutical Biokin (Shanghai) Biopharmaceutical Transcenta Therapeutics (Hangzhou) Shanghai Hengrui Pharmaceutical Innovent Biologics (Suzhou)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.